Drug discovery platform Atomwise snags $123m Series B

San Francisco-based Atomwise, an AI drug discovery company, has raised $123 million in Series B financing.

11 August 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles